Govender T, Riley T, Ehtezazi T, Garnett M C, Stolnik S, Illum L, Davis S S
School of Pharmaceutical Sciences, University of Nottingham, Nottingham, UK.
Int J Pharm. 2000 Apr 10;199(1):95-110. doi: 10.1016/s0378-5173(00)00375-6.
The drug incorporation and physicochemical properties of PLA-PEG micellar like nanoparticles were examined in this study using a model water soluble drug, procaine hydrochloride. Procaine hydrochloride was incorporated into nanoparticles made from a series of PLA-PEG copolymers with a fixed PEG block (5 kDa) and a varying PLA segment (3-110 kDa). The diameter of the PLA-nanoparticles increased from 27.7 to 174.6 nm, with an increase in the PLA molecular weight. However, drug incorporation efficiency remained similar throughout the series. Incorporation of drug into the smaller PLA-PEG nanoparticles made from 3:5, 15:5 and 30:5 copolymers did not influence the particle size, while an increase was observed for the larger systems comprising 75:5 and 110:5 copolymers. An increase in drug content for PLA-PEG 30:5 nanoparticles was achieved by increasing the theoretical loading (quantity of initially present drug). The size of these nanoparticles remained unchanged with the increasing drug content, supporting the proposed micellar type structure of the PLA-PEG 30:5 nanoparticles. The morphology of these systems remained unchanged both at low and high theoretical drug loadings. Formulation variables, such as an increase in the aqueous phase pH, replacement with the base form of the drug and inclusion of lauric acid in the formulation did not improve the incorporation efficiency of drug into PLA-PEG 30:5 nanoparticles. While poly(aspartic acid) as a complexation agent did not improve the drug incorporation efficiency of procaine hydrochloride, it did so for another water soluble drug diminazene aceturate. This may be attributed to a stronger interaction of diminazene aceturate with poly(aspartic acid) relative to procaine hydrochloride, as confirmed by thermodynamic analysis of isothermal titration calorimetric data. The drug incorporation and physicochemical characterisation data obtained in this study may be relevant in optimising the drug incorporation and delivery properties of these potential drug targeting carriers.
本研究使用一种水溶性药物模型——盐酸普鲁卡因,对聚乳酸-聚乙二醇(PLA-PEG)类胶束纳米颗粒的药物包封率和理化性质进行了研究。盐酸普鲁卡因被包封于由一系列PLA-PEG共聚物制成的纳米颗粒中,这些共聚物具有固定的PEG嵌段(5 kDa)和不同的PLA链段(3-110 kDa)。随着PLA分子量的增加,PLA纳米颗粒的直径从27.7 nm增加到174.6 nm。然而,整个系列的药物包封效率保持相似。将药物包封于由3:5、15:5和30:5共聚物制成的较小的PLA-PEG纳米颗粒中,并未影响粒径,而对于由75:5和110:5共聚物组成的较大体系,粒径则有所增加。通过增加理论载药量(初始存在的药物量),实现了PLA-PEG 30:5纳米颗粒药物含量的增加。随着药物含量的增加,这些纳米颗粒的尺寸保持不变,这支持了所提出的PLA-PEG 30:5纳米颗粒的胶束型结构。在低和高理论载药量下,这些体系的形态均保持不变。制剂变量,如水相pH值的增加、用药物的碱形式替代以及在制剂中加入月桂酸,均未提高药物在PLA-PEG 30:5纳米颗粒中的包封效率。虽然聚天冬氨酸作为络合剂并未提高盐酸普鲁卡因的药物包封效率,但对另一种水溶性药物乙酰马杜拉霉素却有提高作用。这可能归因于乙酰马杜拉霉素与聚天冬氨酸之间的相互作用比盐酸普鲁卡因更强,等温滴定量热数据的热力学分析证实了这一点。本研究获得的药物包封和理化特性数据可能与优化这些潜在药物靶向载体的药物包封和递送特性相关。